Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation (original) (raw)
- Letter
- Published: 01 December 2011
- Yan Xia1,
- Haitao Ji1,
- Yanhua Zheng1,
- Ji Liang1,
- Wenhua Huang2,
- Xiang Gao3,
- Kenneth Aldape4 &
- …
- Zhimin Lu1,5,6
Nature volume 480, pages 118–122 (2011)Cite this article
- 21k Accesses
- 824 Citations
- 26 Altmetric
- Metrics details
Subjects
A Corrigendum to this article was published on 05 October 2017
This article has been updated
Abstract
The embryonic pyruvate kinase M2 (PKM2) isoform is highly expressed in human cancer. In contrast to the established role of PKM2 in aerobic glycolysis or the Warburg effect1,2,3, its non-metabolic functions remain elusive. Here we demonstrate, in human cancer cells, that epidermal growth factor receptor (EGFR) activation induces translocation of PKM2, but not PKM1, into the nucleus, where K433 of PKM2 binds to c-Src-phosphorylated Y333 of β-catenin. This interaction is required for both proteins to be recruited to the CCND1 promoter, leading to HDAC3 removal from the promoter, histone H3 acetylation and cyclin D1 expression. PKM2-dependent β-catenin transactivation is instrumental in EGFR-promoted tumour cell proliferation and brain tumour development. In addition, positive correlations have been identified between c-Src activity, β-catenin Y333 phosphorylation and PKM2 nuclear accumulation in human glioblastoma specimens. Furthermore, levels of β-catenin phosphorylation and nuclear PKM2 have been correlated with grades of glioma malignancy and prognosis. These findings reveal that EGF induces β-catenin transactivation via a mechanism distinct from that induced by Wnt/Wingless4 and highlight the essential non-metabolic functions of PKM2 in EGFR-promoted β-catenin transactivation, cell proliferation and tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Change history
01 December 2011
A minor text correction was made in paragraph beginning, 'PCR-amplified human PKM1 was cloned into...'.
References
- Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009)
Article ADS CAS Google Scholar - Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nature Rev. Cancer 11, 85–95 (2011)
Article CAS Google Scholar - Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg’s contributions to current concepts of cancer metabolism. Nature Rev. Cancer 11, 325–337 (2011)
Article CAS Google Scholar - Lu, Z. & Hunter, T. Wnt-independent β-catenin transactivation in tumor development. Cell Cycle 3, 569–571 (2004)
Article Google Scholar - Lu, Z., Jiang, G., Blume-Jensen, P. & Hunter, T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol. Cell. Biol. 21, 4016–4031 (2001)
Article CAS Google Scholar - Wykosky, J., Fenton, T., Furnari, F. & Cavenee, W. K. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin. J. Cancer 30, 5–12 (2011)
Article CAS Google Scholar - Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 (2008)
Article ADS CAS Google Scholar - Yochum, G. S. et al. Serial analysis of chromatin occupancy identifies β-catenin target genes in colorectal carcinoma cells. Proc. Natl Acad. Sci. USA 104, 3324–3329 (2007)
Article ADS CAS Google Scholar - Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181–186 (2008)
Article ADS CAS Google Scholar - Le Mellay, V. et al. Regulation of glycolysis by Raf protein serine/threonine kinases. Adv. Enzyme Regul. 42, 317–332 (2002)
Article CAS Google Scholar - Mazurek, S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969–980 (2011)
Article CAS Google Scholar - Coluccia, A. M. et al. Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 26, 1456–1466 (2007)
Article CAS Google Scholar - Miravet, S. et al. Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates β-catenin-mediated transcription. Mol. Cell. Biol. 23, 7391–7402 (2003)
Article CAS Google Scholar - Xia, Y. et al. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol. Cell 25, 219–232 (2007)
Article CAS Google Scholar - Tetsu, O. & McCormick, F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–426 (1999)
Article ADS CAS Google Scholar - Freije, W. A. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503–6510 (2004)
Article CAS Google Scholar - Gravendeel, L. A. et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 69, 9065–9072 (2009)
Article CAS Google Scholar - Petalidis, L. P. et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol. Cancer Ther. 7, 1013–1024 (2008)
Article CAS Google Scholar - Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173 (2006)
Article CAS Google Scholar - Furnari, F. B. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683–2710 (2007)
Article CAS Google Scholar - Ji, H. et al. EGF-induced ERK activation promotes CK2-mediated disassociation of α-catenin from β-catenin and transactivation of β-catenin. Mol. Cell 36, 547–559 (2009)
Article CAS Google Scholar - Fang, D. et al. Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity. J. Biol. Chem. 282, 11221–11229 (2007)
Article CAS Google Scholar - Lu, Z., Ghosh, S., Wang, Z. & Hunter, T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 4, 499–515 (2003)
Article CAS Google Scholar - Luo, W. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732–744 (2011)
Article CAS Google Scholar - Lu, Z. et al. Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell. Biol. 18, 839–845 (1998)
Article CAS Google Scholar - Gomez-Manzano, C. et al. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin. Cancer Res. 12, 556–562 (2006)
Article CAS Google Scholar
Acknowledgements
We thank T. Hunter (The Salk Institute for Biological Studies) for Abl and Src knockout cells, H. Clevers (Netherlands Institute for Developmental Biology) for the pTOP-FLASH and the pFOP-FLASH, and Y. Li (Baylor College of Medicine) for a WNT1 lenti-vector. This work was supported by National Cancer Institute grants 5R01CA109035 (Z.L.), 5 P50 CA127001-03 and CA16672 (Cancer Center Support Grant); a research grant (RP110252; Z.L.) from the Cancer Prevention and Research Institute of Texas (CPRIT), an American Cancer Society Research Scholar Award RSG-09-277-01-CSM (Z.L.), and a Sister Institution Network Fund from The University of Texas MD Anderson Cancer Center (Z.L.).
Author information
Authors and Affiliations
- Brain Tumor Center and Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA
Weiwei Yang, Yan Xia, Haitao Ji, Yanhua Zheng, Ji Liang & Zhimin Lu - Jiaxing Xinda Biotechnology Company, 1369 Cheng Nan Road, Science and Technology Building, STE 112, Jiaxing, 314000, Zhejiang Province, China
Wenhua Huang - Model Animal Research Center, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210061, China
Xiang Gao - Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA
Kenneth Aldape - Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA
Zhimin Lu - The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, 77030, Texas, USA
Zhimin Lu
Authors
- Weiwei Yang
You can also search for this author inPubMed Google Scholar - Yan Xia
You can also search for this author inPubMed Google Scholar - Haitao Ji
You can also search for this author inPubMed Google Scholar - Yanhua Zheng
You can also search for this author inPubMed Google Scholar - Ji Liang
You can also search for this author inPubMed Google Scholar - Wenhua Huang
You can also search for this author inPubMed Google Scholar - Xiang Gao
You can also search for this author inPubMed Google Scholar - Kenneth Aldape
You can also search for this author inPubMed Google Scholar - Zhimin Lu
You can also search for this author inPubMed Google Scholar
Contributions
This study was conceived by Z.L. Z.L and W.Y. designed the study; W.Y., Y.X., H.J., Y.Z. and J.L. performed experiments; K.A. provided pathology assistance; W.H. and X.G. provided reagents and conceptual advice; Z.L. wrote the paper with comments from all authors.
Corresponding author
Correspondence toZhimin Lu.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
The file contains Supplementary Figures 1-21 with legends, a Supplementary Discussion and Supplementary References. (PDF 8004 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yang, W., Xia, Y., Ji, H. et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation.Nature 480, 118–122 (2011). https://doi.org/10.1038/nature10598
- Received: 10 January 2011
- Revised: 27 September 2011
- Accepted: 06 November 2011
- Published: 01 December 2011
- Issue Date: 01 December 2011
- DOI: https://doi.org/10.1038/nature10598